보고서 요약(국문)

소양증 치료제 시장은 예측 기간(2023-2030년) 동안 연평균 6.1%의 성장률을 보일 것으로 예상됩니다. 소양증 치료제 시장 연구 분석은 정량적 및 정성적 데이터를 포함한 시장에 대한 심층적인 전망을 제공합니다. 시장 세분화를 기반으로 글로벌 시장의 전망과 예측을 제시합니다. 또한 미국, 캐나다, 브라질, 독일, 이탈리아, 스페인, 영국, 러시아, 유럽 국가, 아랍에미리트, 사우디아라비아, 남아프리카공화국, 일본, 중국, 인도, 한국, 호주 및 기타 전 세계 국가를 기준으로 글로벌 소양증 치료제 시장 규모, 성장률, 최신 트렌드, 기회 및 2029년까지의 예측을 제공합니다.
모든 지역 중에서 북미 지역이 예측 기간 동안 글로벌 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. 미국과 캐나다의 소양증 치료제 시장이 가장 큰 비중을 차지할 것으로 전망됩니다. 유럽의 가려움증 치료제 시장은 2023년부터 2030년까지 전 세계적으로 지속적인 성장세를 보일 것으로 예상됩니다.
가려움증 치료제 시장 동향 및 추세
전 세계 가려움증 치료제 시장은 피부 질환의 발생률 증가와 이러한 질환을 치료하기 위한 적절한 진단 및 치료제에 대한 수요 증가 등 여러 요인으로 인해 성장하고 있습니다.
가려움증에 대한 새로운 치료제 개발은 전 세계 시장 성장을 견인하고 있습니다.
다양한 가려움증에 대한 새로운 표적 치료제 개발은 전 세계 가려움증 치료제 시장의 성장을 주도하고 있습니다. 예를 들어, 염증 반응 진행에 관여하는 인터루킨-4 수용체를 특이적으로 표적하는 단클론 항체인 듀플리맙(Duplimab)의 개발과 함께, 크리사보롤 2% 연고(Crisaborole 2% ointment) 등 야누스 키나제 억제제를 포함한 국소 치료제들이 주요 시장 참여 기업들의 파이프라인에 있습니다. 또한, 여러 규제 기관에서 이러한 신규 치료제를 승인함에 따라 시장 성장이 촉진되고 있습니다. 예를 들어, 2022년 6월 사노피가 개발한 듀픽센트(듀플리맙)는 미국 식품의약국(FDA)에서 6개월에서 5세 사이의 소아에서 중등도에서 중증 피부염 치료제로 승인받은 최초의 생물학적 제제입니다. 이러한 시장 동향과 새로운 치료제 개발은 전 세계적으로 시장 성장을 견인하고 있습니다.
하지만, 치료제에 대한 인식 부족과 약물 부작용 발생률은 가려움증 치료제 시장 성장에 걸림돌이 될 수 있습니다.

특히, 가려움증 치료제에 대한 인식 부족과 치료제 관련 부작용에 대한 우려는 시장 성장을 저해하는 요인입니다.

산업 분석
소양증 치료제 시장 보고서는 포터의 5가지 경쟁력 분석, 연구 개발, 역학, 규제 분석, 가격 분석 및 파이프라인 분석 등 다양한 산업 요인을 기반으로 시장에 대한 심층 분석을 제공합니다.
코로나19가 소양증 치료제 시장에 미치는 영향 분석
미국 접촉피부염학회는 코로나19 팬데믹으로 접촉피부염 환자가 증가했다고 밝혔습니다. 코로나19 유행 기간 동안 미국 질병통제예방센터(CDC)는 비누, 세제, 알코올 함유 손 소독제를 이용한 반복적인 손 위생을 권장했는데, 이는 피부 장벽의 완전성과 기능 변화를 초래하여 피부염 발생 위험을 높였습니다. 또한, 코로나19 발생 기간 동안 의료 종사자들에게 개인 보호 장비(PPE) 착용이 권장되면서 접촉피부염을 경험하는 의료 종사자의 수가 증가했고, 이는 소양증 치료제 시장에 긍정적인 영향을 미쳤습니다.

가려움증 치료제 시장 세분화 분석
코르티코스테로이드는 예측 기간(2023-2030년) 동안 가려움증 치료제 시장을 주도할 것으로 예상됩니다.
코르티코스테로이드 부문은 2021년에 가장 높은 시장 점유율을 차지했으며, 아토피 피부염, 알레르기 접촉 피부염, 건선, 편평태선과 같은 중등도에서 중증의 염증성 피부 질환과 관련된 급성 가려움증에 대한 1차 치료제로 널리 사용되기 때문에 예측 기간(2022-2029년) 동안에도 가려움증 치료제 시장을 주도할 것으로 예상됩니다. 코르티코스테로이드는 글루코코르티코이드 수용체를 활성화하여 사이토카인 활성화를 억제함으로써 국소 염증을 감소시키고 간접적으로 가려움증을 조절합니다. 미국에서는 30가지가 넘는 다양한 국소 스테로이드 제제가 시판되고 있으며, 이들은 용액, 로션, 크림 또는 연고 등 다양한 제형으로 제조됩니다. 국소 코르티코스테로이드는 효능이 낮은(7등급) 것부터 높은 또는 초강력(1등급)까지 다양합니다. 염증, 그리고 간접적으로 가려움증 치료에 대한 임상적 효능은 스테로이드 효능과 상관관계가 있는 것으로 일반적으로 받아들여지고 있습니다.
가려움증 치료제 시장 지역별 점유율
북미는 가려움증 치료제 시장을 주도하고 있습니다.
북미는 2021년 가려움증 치료제 시장을 지배했습니다. 대부분의 주요 시장 참여 기업들이 북미에 본사를 두고 생물학적 제제와 같은 새로운 약물 치료법 개발에 참여하고 있기 때문에 북미는 예측 기간(2022-2029) 동안 전 세계 가려움증 치료제 시장을 주도할 것으로 예상됩니다. 대표적인 기업으로는 Bausch Health, Astellas Pharma U.S. Inc., Pfizer Inc., Mylan, Bayer AG, Allergen, Eli Lilly 등이 있습니다. 또한, 의료 부문의 발전으로 인해 여러 기관과 단체들이 가려움증에 대한 관심을 적극적으로 기울이고 있으며, 정부 차원에서도 가려움증에 대한 인식을 확산하기 위한 다양한 노력을 기울이고 있습니다. 예를 들어, 1989년에 설립된 미국 접촉성 피부염 협회(American Contact Dermatitis Society)는 2,500명 이상의 의료 전문가를 보유하고 있으며, 가려움증 및 관련 피부 염증 질환 분야에 집중하고 있습니다. 또한, 북미 접촉성 피부염 그룹(North American Contact Dermatitis Group)은 수많은 사람들이 정보에 기반한 근거 중심의 피부 관리 결정을 내릴 수 있도록 지원하고 있습니다. 이러한 사실들은 북미 지역이 예측 기간 동안 가려움증 치료제 시장을 주도할 것임을 보여줍니다.
가려움증 치료제 기업 및 경쟁 환경
가려움증 치료제 시장은 경쟁이 치열하며, 몇몇 주요 업체들이 시장 점유율 확보를 위해 경쟁하고 있습니다. 전 세계 가려움증 치료제 시장의 주요 업체로는 Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd, Pfizer, Sanofi, GlaxoSmithKline, Merck 등이 있습니다. 주요 업체들은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 성장 전략을 통해 전 세계 가려움증 치료제 시장의 성장에 기여하고 있습니다. 예를 들어, 2022년 1월 Pfizer는 성인 피부염 치료를 위한 경구용 1일 1회 복용 야누스 키나제 억제제인 Cibinqo(Adrocitinib)에 대해 미국 FDA 승인을 획득했습니다. 또한, 2022년 4월 Leo Pharma는 Adbry(Tralokinumab-ldrm)의 장기 효능에 대한 중간 데이터를 발표했습니다. 이러한 사례들은 가려움증 치료제 시장의 경쟁 구도를 더욱 심화시키고 있습니다.
레오 파마
개요
레오 파마는 1908년에 설립되어 덴마크에 본사를 둔 피부과 시장의 선도 기업입니다. 피부과 과학 발전을 위한 연구 개발에 주력하고 있습니다.
제품 포트폴리오
레오 파마의 피부과 제품 포트폴리오에는 Adtralza, Dovobet, Dovonex, Enstilar, Finacea, Kyntheum, Protopic, Skinoren, Fucidin, Fucibet 등이 있습니다.
글로벌 가려움증 치료제 시장 보고서는 약 40개 이상의 시장 데이터 표, 45개 이상의 그림, 그리고 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Pruritus Therapeutics Market is estimated to reach at a CAGR of 6.1% during the forecast period (2023-2030). Pruritus Therapeutics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Pruritus Therapeutics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Pruritus Therapeutics Market in the United States and Canada produces the utmost share. Whereas the European Pruritus Therapeutics Market is projected to continue its presence globally during the period of 2023- 2030.
Pruritus Therapeutics Market Dynamics and Trends
The global pruritus therapeutics market is growing due to several factors, such as the increasing incidence of dermatological disorders influencing the occurrence of pruritus and the growing demand for proper diagnostics and therapeutics to treat such medical conditions.
The development of new therapeutics for pruritus is forcing global market growth.
The development of new targeted therapies for different pruritus is driving the growth of the global pruritus therapeutics market. For instance, the development of Duplimab, which is a monoclonal antibody that specifically targets interleukin-4 receptors that are involved in the progression of the inflammatory response with these other novel therapeutics, for example, Crisaborole 2% ointment and others are in the pipeline of major key market players for topical medication including the Janus kinase inhibitors. Furthermore, the approval of these newly developed therapeutics by different regulatory bodies propels the market towards growth. For instance, in June 2022, Dupixent (Duplimab), developed by Sanofi, is the first biologics medicine validated by the United States Food and Drug Administration to treat moderate to severe dermatitis in children aged 6 months to 5 years. These market events and the development of new therapeutics are fueling the market growth globally.
The lack of awareness and incidences of drug side effects will become a hurdle in the pruritus therapeutics market growth.
However, the lack of awareness towards therapeutics for pruritus and the associated side effects associated with pruritus therapeutics hinder the market's growth.
Industry analysis
The pruritus therapeutics market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory analysis, pricing analysis and pipeline analysis, Etc.
COVID-19 Impact Analysis on Pruritus Therapeutics Market
The American Contact Dermatitis Society informed that the covid-19 pandemic had increased the number of contact dermatitis cases. Amidst covid-19, the CDC recommended repetitive hand hygiene with soaps, detergents, and hand sanitization through alcohol-containing hand sanitizers, which lead to the integrity and integrity function alteration in the skin barrier, raising the risk of dermatitis. Also, during the covid-19 outbreak, healthcare professionals were suggested to employ personal protective kits, which have caused a rise in the number of healthcare professionals experiencing contact dermatitis, positively impacting the pruritus therapeutics market.
Pruritus Therapeutics Market Segmentation Analysis
The corticosteroids will dominate the pruritus therapeutics market during the forecast period (2023-2030).
The corticosteroids segment accounted for the highest market share in 2021 and is expected to dominate the Pruritus therapeutics market during the forecast period (2022-2029) since corticosteroids are widely used as the first line of treatment for acute pruritus associated with moderate to severe inflammatory skin diseases, such as AD, allergic contact dermatitis, psoriasis and lichen planus. Corticosteroids are activated glucocorticoid receptors that inhibit cytokine activation, thereby decreasing local inflammation and indirectly controlling pruritus. More than 30 different topical steroid formulations are available in the United States, and these are prepared on different bases (e.g., solution, lotion, cream or ointment). Topical corticosteroids range in potency from low (Class VII) to high or ultra-potent (Class I). It is generally accepted that the clinical efficacy to treat inflammation, and indirectly pruritus, correlates with steroid potency.
Pruritus Therapeutics Market Geographical Share
North America is subjugating the pruritus therapeutics market.
North America dominated the pruritus therapeutics market in 2021. It is estimated that North America will command the global pruritus therapeutics market during the forecast period (2022-2029) since most key market players are headquartered in North America and are involved in developing new drug therapies such as biologics. Examples are Bausch Health, Astellas Pharma U.S.Inc., Pfizer Inc., Mylan, Bayer AG, Allergen, Eli Lilly, and many more. Also, owing to the health care sector developments, organizations and societies are actively looking out for pruritus and government initiatives for spreading awareness about pruritus. For instance, founded in 1989, the American Contact Dermatitis Society is focused on pruritus with over 2,500 healthcare professionals in the field of pruritus and related skin inflammatory diseases. Also, the North American Contact Dermatitis Group is helping thousands of people make informed, evidence-based skin care decisions. These facts show that the North American region will dominate the pruritus therapeutics market over the forecast period.
Pruritus Therapeutics Companies and Competitive Landscape
The pruritus therapeutics market is competitive, with few major players competing to gain market share. Some major players in the global pruritus therapeutics market include Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd, Pfizer, Sanofi, GlaxoSmithKline, Merck, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the global Pruritus Therapeutics market's growth. For instance, in January 2022, Pfizer acquired U.S.FDA approval for its Cibinqo (Adrocitinib), an oral once-a-day Janus kinase inhibitor for treating adults suffering from dermatitis. Also, in April 2022, Leo Pharma presented its interim long-term efficacy data for Adbry (Tralokinumab-ldrm). Such incidences create a competitive environment in the Pruritus Therapeutics market.
Leo Pharma
Overview
Leo Pharma is a leading company in the dermatology market, founded in 1908 and headquartered in Denmark. It is primarily focused on research and development to advance the science of dermatology.
Product Portfolio
Leo Pharma’s dermatological product portfolio has Adtralza, Dovobet, Dovonex, Enstilar, Finacea, Kyntheum, Protopic, Skinoren, Fucidin, and Fucibet.
The global pruritus therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) page.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Research and Development
4.1.1.2. Increased Awareness
4.1.1.3. Market Strategies
4.1.2. Restraints
4.1.2.1. Treatment Side Effects
4.1.2.2. Stringent Regulatory Bodies
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Epidemiological Analysis
5.3. Research and Developments
5.4. Pipeline Analysis
5.5. Supply Chain Analysis
5.6. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
7.1.2. Market Attractiveness Index, By Disease Type Segment
7.2. Atopic Dermatitis
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Allergic Contact Dermatitis
7.4. Urticaria
7.5. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
8.1.2. Market Attractiveness Index, By Route of Administration Segment
8.2. Oral
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Injectables
8.4. Topical
9. By Drug Class
9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
9.3. Market Attractiveness Index, By Drug Class Segment
9.4. Antihistaminic
9.5. Introduction
9.6. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.7. Corticosteroids
9.8. Counterirritants
9.9. Local Anesthetics
9.10. Calcineurin Inhibitors
9.11. Immunosuppressant
9.12. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
10.1.2. Market Attractiveness Index, By Distribution Channel Segment
10.2. Hospital Pharmacy
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacy
10.4. Online Pharmacy
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
13. Company Profiles
13.1. Leo Pharma
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Bausch Health
13.3. Astellas Pharma U.S.Inc.
13.4. Pfizer Inc.
13.5. Mylan
13.6. Bayer AG
13.7. Allergen
13.8. Sanofi
13.9. Eli Lilly
13.10. Sandoz Inc.(*LIST NOT EXHAUSTIVE)
14. DataM Intelligence
14.1. Appendix
14.2. About Us and Services
14.3. Contact us

언급된 주요 기업들

Leo Pharma, Bausch Health, Astellas Pharma U.S.Inc., Pfizer Inc., Mylan, Bayer AG, Allergen, Sanofi, Eli Lilly

표 목록 (Tables)

List of Tables

Table No. 1 Global Pruritus Therapeutics Market Value, By Disease Type, 2023, 2027 & 2031 ($ Million)

Table No. 2 Global Pruritus Therapeutics Market Value, By Route of Administration, 2023, 2027 & 2031 ($ Million)

Table No. 3 Global Pruritus Therapeutics Market Value, By Drug Class, 2023, 2027 & 2031 ($ Million)

Table No. 4 Global Pruritus Therapeutics Market Value, By Distribution Channel, 2023, 2027 & 2031 ($ Million)

Table No. 5 Global Pruritus Therapeutics Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table No. 6 Global Pruritus Therapeutics Market Value, By Disease Type, 2023, 2027 & 2031 ($ Million)

Table No. 7 Global Pruritus Therapeutics Market Value, By Disease Type, 2022-2031 ($ Million)

Table No. 8 Global Pruritus Therapeutics Market Value, By Route of Administration, 2023, 2027 & 2031 ($ Million)

Table No. 9 Global Pruritus Therapeutics Market Value, By Route of Administration, 2022-2031 ($ Million)

Table No. 10 Global Pruritus Therapeutics Market Value, By Drug Class, 2023, 2027 & 2031 ($ Million)

Table No. 11 Global Pruritus Therapeutics Market Value, By Drug Class, 2022-2031 ($ Million)

Table No. 12 Global Pruritus Therapeutics Market Value, By Distribution Channel, 2023, 2027 & 2031 ($ Million)

Table No. 13 Global Pruritus Therapeutics Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table No. 14 Global Pruritus Therapeutics Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table No. 15 Global Pruritus Therapeutics Market Value, By Region, 2022-2031 ($ Million)

Table No. 16 North America Pruritus Therapeutics Market Value, By Disease Type, 2022-2031 ($ Million)

Table No. 17 North America Pruritus Therapeutics Market Value, By Route of Administration, 2022-2031 ($ Million)

Table No. 18 North America Pruritus Therapeutics Market Value, By Drug Class, 2022-2031 ($ Million)

Table No. 19 North America Pruritus Therapeutics Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table No. 20 North America Pruritus Therapeutics Market Value, By Country, 2022-2031 ($ Million)

Table No. 21 South America Pruritus Therapeutics Market Value, By Disease Type, 2022-2031 ($ Million)

Table No. 22 South America Pruritus Therapeutics Market Value, By Route of Administration, 2022-2031 ($ Million)

Table No. 23 South America Pruritus Therapeutics Market Value, By Drug Class, 2022-2031 ($ Million)

Table No. 24 South America Pruritus Therapeutics Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table No. 25 South America Pruritus Therapeutics Market Value, By Country, 2022-2031 ($ Million)

Table No. 26 Europe Pruritus Therapeutics Market Value, By Disease Type, 2022-2031 ($ Million)

Table No. 27 Europe Pruritus Therapeutics Market Value, By Route of Administration, 2022-2031 ($ Million)

Table No. 28 Europe Pruritus Therapeutics Market Value, By Drug Class, 2022-2031 ($ Million)

Table No. 29 Europe Pruritus Therapeutics Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table No. 30 Europe Pruritus Therapeutics Market Value, By Country, 2022-2031 ($ Million)

Table No. 31 Asia-Pacific Pruritus Therapeutics Market Value, By Disease Type, 2022-2031 ($ Million)

Table No. 32 Asia-Pacific Pruritus Therapeutics Market Value, By Route of Administration, 2022-2031 ($ Million)

Table No. 33 Asia-Pacific Pruritus Therapeutics Market Value, By Drug Class, 2022-2031 ($ Million)

Table No. 34 Asia-Pacific Pruritus Therapeutics Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table No. 35 Asia-Pacific Pruritus Therapeutics Market Value, By Country, 2022-2031 ($ Million)

Table No. 36 Middle East & Africa Pruritus Therapeutics Market Value, By Disease Type, 2022-2031 ($ Million)

Table No. 37 Middle East & Africa Pruritus Therapeutics Market Value, By Route of Administration, 2022-2031 ($ Million)

Table No. 38 Middle East & Africa Pruritus Therapeutics Market Value, By Drug Class, 2022-2031 ($ Million)

Table No. 39 Middle East & Africa Pruritus Therapeutics Market Value, By Distribution Channel, 2022-2031 ($ Million)

Table No. 40 Leo Pharma: Overview

Table No. 41 Leo Pharma: Product Portfolio

Table No. 42 Leo Pharma: Key Developments

Table No. 43 Bausch Health: Overview

Table No. 44 Bausch Health: Product Portfolio

Table No. 45 Bausch Health: Key Developments

Table No. 46 Astellas Pharma U.S.Inc.: Overview

Table No. 47 Astellas Pharma U.S.Inc.: Product Portfolio

Table No. 48 Astellas Pharma U.S.Inc.: Key Developments

Table No. 49 Pfizer Inc.: Overview

Table No. 50 Pfizer Inc.: Product Portfolio

Table No. 51 Pfizer Inc.: Key Developments

Table No. 52 Mylan: Overview

Table No. 53 Mylan: Product Portfolio

Table No. 54 Mylan: Key Developments

Table No. 55 Bayer AG: Overview

Table No. 56 Bayer AG: Product Portfolio

Table No. 57 Bayer AG: Key Developments

Table No. 58 Allergen: Overview

Table No. 59 Allergen: Product Portfolio

Table No. 60 Allergen: Key Developments

Table No. 61 Sanofi: Overview

Table No. 62 Sanofi: Product Portfolio

Table No. 63 Sanofi: Key Developments

Table No. 64 Eli Lilly: Overview

Table No. 65 Eli Lilly: Product Portfolio

Table No. 66 Eli Lilly: Key Developments

Table No. 67 Sandoz Inc.: Overview

Table No. 68 Sandoz Inc.: Product Portfolio

Table No. 69 Sandoz Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure No. 1 Global Pruritus Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure No. 2 Global Pruritus Therapeutics Market Share, By Route of Administration, 2022 & 2031 (%)

Figure No. 3 Global Pruritus Therapeutics Market Share, By Drug Class, 2022 & 2031 (%)

Figure No. 4 Global Pruritus Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure No. 5 Global Pruritus Therapeutics Market Share, By Region, 2022 & 2031 (%)

Figure No. 6 Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 7 Global Pruritus Therapeutics Market Y-o-Y Growth, By Disease Type, 2022-2031 (%)

Figure No. 8 Atopic Dermatitis: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 9 Allergic Contact Dermatitis: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 10 Urticaria: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 11 Others: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 12 Global Pruritus Therapeutics Market Y-o-Y Growth, By Route of Administration, 2022-2031 (%)

Figure No. 13 Oral: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 14 Injectables: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 15 Topical: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 16 Global Pruritus Therapeutics Market Y-o-Y Growth, By Drug Class, 2022-2031 (%)

Figure No. 17 Antihistaminic: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 18 Corticosteroids: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 19 Counterirritants: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 20 Local Anesthetics: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 21 Calcineurin Inhibitors: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 22 Immunosuppressant: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 23 Others: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 24 Global Pruritus Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure No. 25 Hospital Pharmacy: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 26 Retail Pharmacy: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 27 Online Pharmacy: Global Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 28 Global Pruritus Therapeutics Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure No. 29 North America Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 30 North America Pruritus Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure No. 31 North America Pruritus Therapeutics Market Share, By Route of Administration, 2022 & 2031 (%)

Figure No. 32 North America Pruritus Therapeutics Market Share, By Drug Class, 2022 & 2031 (%)

Figure No. 33 North America Pruritus Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure No. 34 North America Pruritus Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure No. 35 South America Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 36 South America Pruritus Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure No. 37 South America Pruritus Therapeutics Market Share, By Route of Administration, 2022 & 2031 (%)

Figure No. 38 South America Pruritus Therapeutics Market Share, By Drug Class, 2022 & 2031 (%)

Figure No. 39 South America Pruritus Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure No. 40 South America Pruritus Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure No. 41 Europe Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 42 Europe Pruritus Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure No. 43 Europe Pruritus Therapeutics Market Share, By Route of Administration, 2022 & 2031 (%)

Figure No. 44 Europe Pruritus Therapeutics Market Share, By Drug Class, 2022 & 2031 (%)

Figure No. 45 Europe Pruritus Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure No. 46 Europe Pruritus Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure No. 47 Asia-Pacific Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 48 Asia-Pacific Pruritus Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure No. 49 Asia-Pacific Pruritus Therapeutics Market Share, By Route of Administration, 2022 & 2031 (%)

Figure No. 50 Asia-Pacific Pruritus Therapeutics Market Share, By Drug Class, 2022 & 2031 (%)

Figure No. 51 Asia-Pacific Pruritus Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure No. 52 Asia-Pacific Pruritus Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure No. 53 Middle East & Africa Pruritus Therapeutics Market Value, 2022-2031 ($ Million)

Figure No. 54 Middle East & Africa Pruritus Therapeutics Market Share, By Disease Type, 2022 & 2031 (%)

Figure No. 55 Middle East & Africa Pruritus Therapeutics Market Share, By Route of Administration, 2022 & 2031 (%)

Figure No. 56 Middle East & Africa Pruritus Therapeutics Market Share, By Drug Class, 2022 & 2031 (%)

Figure No. 57 Middle East & Africa Pruritus Therapeutics Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure No. 58 Leo Pharma: Financials

Figure No. 59 Bausch Health: Financials

Figure No. 60 Astellas Pharma U.S.Inc.: Financials

Figure No. 61 Pfizer Inc.: Financials

Figure No. 62 Mylan: Financials

Figure No. 63 Bayer AG: Financials

Figure No. 64 Allergen: Financials

Figure No. 65 Sanofi: Financials

Figure No. 66 Eli Lilly: Financials

Figure No. 67 Sandoz Inc.: Financials